Bueno-Muino C, Echavarria I, Lopez-Tarruella S, Roche-Molina M, Del Monte-Millan M, Massarrah T, Jerez Y, Ayala de la Pena F, Garcia-Saenz JA, Moreno F, Rodriguez-Lescure A, Malon-Gimenez D, Ballesteros Garcia AI, Marin-Aguilera M, Galvan P, Braso-Maristany F, Waks AG, Tolaney SM, Mittendorf EA, Vivancos A, Villagrasa P, Parker JS, Perou CM, Pare L, Villacampa G, Prat A, Martin M. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. JAMA Oncol. 2023 Jun 1;9(6):841-846. doi: 10.1001/jamaoncol.2023.0187. PubMed PMID: 37103916; PubMed Central PMCID: PMC10141274.
AÑO: 2023; IF: 22.5